Recommendations for physical activity and recreational sports participation for young patients with genetic cardiovascular diseases.

A group of relatively uncommon but important genetic cardiovascular diseases (GCVDs) are associated with increased risk for sudden cardiac death during exercise, including hypertrophic cardiomyopathy, long-QT syndrome, Marfan syndrome, and arrhythmogenic right ventricular cardiomyopathy. These conditions, characterized by diverse phenotypic expression and genetic substrates, account for a substantial proportion of unexpected and usually arrhythmia-based fatal events during adolescence and young adulthood. Guidelines are in place governing eligibility and disqualification criteria for competitive athletes with these GCVDs (eg, Bethesda Conference No. 26 and its update as Bethesda Conference No. 36 in 2005). However, similar systematic recommendations for the much larger population of patients with GCVD who are not trained athletes, but nevertheless wish to participate in any of a variety of recreational physical activities and sports, have not been available. The practicing clinician is frequently confronted with the dilemma of designing noncompetitive exercise programs for athletes with GCVD after disqualification from competition, as well as for those patients with such conditions who do not aspire to organized sports. Indeed, many asymptomatic (or mildly symptomatic) patients with GCVD desire a physically active lifestyle with participation in recreational and leisure-time activities to take advantage of the many documented benefits of exercise. However, to date, no reference document has been available for ascertaining which types of physical activity could be regarded as either prudent or inadvisable in these subgroups of patients. Therefore, given this clear and present need, this American Heart Association consensus document was constituted, based largely on the experience and insights of the expert panel, to offer recommendations governing recreational exercise for patients with known GCVDs.

[1]  M. Leppert,et al.  The spectrum of symptoms and QT intervals in carriers of the gene for the long-QT syndrome. , 1992, The New England journal of medicine.

[2]  Correia Mj.  [Molecular diagnosis of the inherited long-QT syndrome in a woman who died after near-drowning]. , 2000 .

[3]  R. Hauer,et al.  Genetic and Molecular Basis of Cardiac Arrhythmias: Impact on Clinical Management , 2022 .

[4]  B. Maron,et al.  The paradox of exercise. , 2000, The New England journal of medicine.

[5]  G. Breithardt,et al.  [Task Force on Sudden Cardiac Death, European Society of Cardiology. Summary of recommendations]. , 2002, Italian heart journal. Supplement : official journal of the Italian Federation of Cardiology.

[6]  A. Tajik,et al.  Prevalence and Severity of “Benign” Mutations in the β-Myosin Heavy Chain, Cardiac Troponin T, and α-Tropomyosin Genes in Hypertrophic Cardiomyopathy , 2002, Circulation.

[7]  D. Tester,et al.  Swimming, a gene-specific arrhythmogenic trigger for inherited long QT syndrome. , 1999, Mayo Clinic proceedings.

[8]  D. Stephan,et al.  Identification of mutations in the cardiac ryanodine receptor gene in families affected with arrhythmogenic right ventricular cardiomyopathy type 2 (ARVD2). , 2001, Human molecular genetics.

[9]  R. Liberthson,et al.  Sudden death from cardiac causes in children and young adults. , 1996, The New England journal of medicine.

[10]  S. Priori,et al.  Influence of the genotype on the clinical course of the long-QT syndrome. International Long-QT Syndrome Registry Research Group. , 1998, The New England journal of medicine.

[11]  J. Mitchell,et al.  Revised eligibility recommendations for competitive athletes with cardiovascular abnormalities. , 1994, Medicine and science in sports and exercise.

[12]  F O Mueller,et al.  Sudden death in young competitive athletes. Clinical, demographic, and pathological profiles. , 1996, JAMA.

[13]  M. Link,et al.  Report of the NASPE Policy Conference on Arrhythmias and the Athlete , 2001, Journal of cardiovascular electrophysiology.

[14]  A. Moss,et al.  Images in clinical medicine. Internal ventricular defibrillation. , 2000, The New England journal of medicine.

[15]  W. Edwards,et al.  Molecular diagnosis of the inherited long-QT syndrome in a woman who died after near-drowning. , 1999, The New England journal of medicine.

[16]  G Thiene,et al.  Hypertrophic cardiomyopathy and sudden death in the young: pathologic evidence of myocardial ischemia. , 2000, Human pathology.

[17]  A. Moss,et al.  Impact of laboratory molecular diagnosis on contemporary diagnostic criteria for genetically transmitted cardiovascular diseases:hypertrophic cardiomyopathy, long-QT syndrome, and Marfan syndrome. A statement for healthcare professionals from the Councils on Clinical Cardiology, Cardiovascular Disea , 1998, Circulation.

[18]  Barry J Maron,et al.  American College of Cardiology/European Society of Cardiology clinical expert consensus document on hypertrophic cardiomyopathy. A report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents and the European Society of Cardiology Committee for Practice G , 2003, Journal of the American College of Cardiology.

[19]  U Ravens,et al.  Task Force on Sudden Cardiac Death of the European Society of Cardiology. , 2001, European heart journal.

[20]  Barry I. Maron.  Cardiovascular Risks to Young Persons on the Athletic Field , 1998, Annals of Internal Medicine.

[21]  R. A. Krause.  Complexes of 2-Hydroxyethyliminodiacetic Acid , 1963 .

[22]  S. Priori,et al.  Long QT syndrome patients with mutations of the SCN5A and HERG genes have differential responses to Na+ channel blockade and to increases in heart rate. Implications for gene-specific therapy. , 1995, Circulation.

[23]  J E Smialek,et al.  Sports-related and non-sports-related sudden cardiac death in young adults. , 1991, American heart journal.

[24]  M. Davies,et al.  Spectrum of clinicopathologic manifestations of arrhythmogenic right ventricular cardiomyopathy/dysplasia: a multicenter study. , 1997, Journal of the American College of Cardiology.

[25]  M. Link,et al.  Implantable Cardioverter-Defibrillator Therapy for Prevention of Sudden Death in Patients With Arrhythmogenic Right Ventricular Cardiomyopathy/Dysplasia , 2003, Circulation.

[26]  P. Coumel,et al.  Catecholaminergic polymorphic ventricular tachycardia in children. A 7-year follow-up of 21 patients. , 1995, Circulation.

[27]  M. Link,et al.  Efficacy of implantable cardioverter-defibrillators for the prevention of sudden death in patients with hypertrophic cardiomyopathy. , 2000, The New England journal of medicine.

[28]  M. Link,et al.  Adverse cardiovascular events temporally associated with Ma Huang, an herbal source of ephedrine☆ , 2002 .

[29]  C Antzelevitch,et al.  Ionic mechanisms responsible for the electrocardiographic phenotype of the Brugada syndrome are temperature dependent. , 1999, Circulation research.

[30]  B. Maron,et al.  Competitive athletes with cardiovascular disease--the case of Nicholas Knapp. , 1998, The New England journal of medicine.

[31]  J. Manson,et al.  Triggering of sudden death from cardiac causes by vigorous exertion. , 2000, The New England journal of medicine.

[32]  D. Corrado,et al.  Right ventricular cardiomyopathy and sudden death in young people. , 1988, The New England journal of medicine.

[33]  K. Bailey,et al.  Sudden unexpected nontraumatic deaths in young adults: A 30-year population-based study , 1991 .

[34]  E. Giardina,et al.  Benefits, adverse effects and drug interactions of herbal therapies with cardiovascular effects. , 2002, Journal of the American College of Cardiology.

[35]  D. Corrado,et al.  Screening for hypertrophic cardiomyopathy in young athletes. , 1998, The New England journal of medicine.

[36]  S. Priori,et al.  Age- and sex-related differences in clinical manifestations in patients with congenital long-QT syndrome: findings from the International LQTS Registry. , 1998, Circulation.

[37]  M. Silka,et al.  Mechanism of sudden cardiac arrest while swimming in a child with the prolonged QT syndrome. , 2002, The Journal of pediatrics.

[38]  L. Hillis,et al.  Cardiovascular complications of cocaine use. , 2001, The New England journal of medicine.

[39]  A. Tajik,et al.  Prevalence and age-dependence of malignant mutations in the beta-myosin heavy chain and troponin T genes in hypertrophic cardiomyopathy: a comprehensive outpatient perspective. , 2002, Journal of the American College of Cardiology.

[40]  D. Corrado,et al.  Right Bundle Branch Block, Right Precordial ST-Segment Elevation, and Sudden Death in Young People , 2001, Circulation.

[41]  D. Clapham,et al.  Ion channels--basic science and clinical disease. , 1997, The New England journal of medicine.

[42]  G. Danieli,et al.  Mutation in human desmoplakin domain binding to plakoglobin causes a dominant form of arrhythmogenic right ventricular cardiomyopathy. , 2002, American journal of human genetics.

[43]  B. Maron,et al.  Development and progression of left ventricular hypertrophy in children with hypertrophic cardiomyopathy. , 1986, The New England journal of medicine.

[44]  B. Chaitman,et al.  Recommendations for cardiovascular screening, staffing, and emergency policies at health/fitness facilities. , 1998, Circulation.

[45]  B. Maron.  Hypertrophic cardiomyopathy: a systematic review. , 2002, JAMA.

[46]  J. Mitchell,et al.  Revised eligibility recommendations for competitive athletes with cardiovascular abnormalities. , 1994, Journal of the American College of Cardiology.

[47]  L. McLain,et al.  Sudden death in young athletes. , 2003, Pediatric annals.

[48]  B. Maron,et al.  Effect of left ventricular outflow tract obstruction on clinical outcome in hypertrophic cardiomyopathy. , 2003, The New England journal of medicine.

[49]  H. Dietz,et al.  Mutations in the human gene for fibrillin-1 (FBN1) in the Marfan syndrome and related disorders. , 1995, Human molecular genetics.

[50]  D. Corrado,et al.  Sudden death in young competitive athletes: clinicopathologic correlations in 22 cases. , 1990, The American journal of medicine.

[51]  J. Seidman,et al.  Characteristics and prognostic implications of myosin missense mutations in familial hypertrophic cardiomyopathy. , 1992, The New England journal of medicine.

[52]  J. Haller,et al.  Pneumothorax in the Marfan syndrome: prevalence and therapy. , 1984, The Annals of thoracic surgery.

[53]  Carlo Napolitano,et al.  Clinical and Molecular Characterization of Patients With Catecholaminergic Polymorphic Ventricular Tachycardia , 2002, Circulation.

[54]  J. Seidman,et al.  The Genetic Basis for Cardiomyopathy from Mutation Identification to Mechanistic Paradigms , 2001, Cell.

[55]  M. Ackerman,et al.  Role of transvenous implantable cardioverter-defibrillators in preventing sudden cardiac death in children, adolescents, and young adults. , 2002, Mayo Clinic proceedings.

[56]  K. P. Carney,et al.  Relationship of race to sudden cardiac death in competitive athletes with hypertrophic cardiomyopathy. , 2003, Journal of the American College of Cardiology.

[57]  H Niimura,et al.  Development of left ventricular hypertrophy in adults in hypertrophic cardiomyopathy caused by cardiac myosin-binding protein C gene mutations. , 2001, Journal of the American College of Cardiology.

[58]  K Shimomura,et al.  The circadian pattern of the development of ventricular fibrillation in patients with Brugada syndrome. , 1999, European heart journal.

[59]  W. Shen,et al.  Epinephrine-induced QT interval prolongation: a gene-specific paradoxical response in congenital long QT syndrome. , 2002, Mayo Clinic proceedings.

[60]  J. Towbin.  Molecular genetic basis of sudden cardiac death. , 2001, Cardiovascular pathology : the official journal of the Society for Cardiovascular Pathology.

[61]  H. Hecht.  Recommendations for preparticipation screening and the assessment of cardiovascular disease in masters athletes. , 2001, Circulation.

[62]  F. Katsukawa,et al.  Aortic root dilatation among young competitive athletes: echocardiographic screening of 1929 athletes between 15 and 34 years of age. , 2000, American heart journal.

[63]  B. Maron,et al.  26th Bethesda Conferance: Recommendations for determining eligibility for competetion in athletes with cardiovascular abnormalities , 1994 .

[64]  J. Mitchell,et al.  16th Bethesda Conference: Cardiovascular abnormalities in the athlete: recommendations regarding eligibility for competition. October 3-5, 1984. , 1985, Journal of the American College of Cardiology.

[65]  Paul J. Wang,et al.  Arrhythmogenic Right Ventricular Dysplasia: Clinical Results with Implantable Cardioverter Defibrillators , 1997, Journal of Interventional Cardiac Electrophysiology.

[66]  M. Mitten.  Team Physicians and Competitive Athletes: Allocating Legal Responsibility for Athletic Injuries , 1993 .

[67]  G. Breithardt,et al.  Life-threatening Arrhythmias Genotype-phenotype Correlation in the Long-qt Syndrome : Gene-specific Triggers for Genotype-phenotype Correlation in the Long-qt Syndrome Gene-specific Triggers for Life-threatening Arrhythmias , 2022 .

[68]  R. Wing,et al.  Successful weight loss maintenance. , 2003, Annual review of nutrition.

[69]  S. Oparil,et al.  Physical activity and cardiovascular health , 1996 .

[70]  A. Moss,et al.  Ventricular Fibrillation During Swimming in a Patient With Long-QT Syndrome , 2002 .

[71]  B. McCrindle,et al.  General cardiology: abstractLong-term outcome in patients with Marfan syndrome: is aortic dissection the only cause of sudden death?☆ , 2003 .

[72]  A. Moss,et al.  Images in cardiovascular medicine. Ventricular fibrillation during swimming in a patient with long-QT syndrome. , 2002, Circulation.

[73]  B. Maron,et al.  Phenotypic spectrum and patterns of left ventricular hypertrophy in hypertrophic cardiomyopathy: morphologic observations and significance as assessed by two-dimensional echocardiography in 600 patients. , 1995, Journal of the American College of Cardiology.

[74]  Maurizio Schiavon,et al.  Does sports activity enhance the risk of sudden death in adolescents and young adults? , 2003, Journal of the American College of Cardiology.

[75]  R. Myerburg,et al.  Scientific Gaps in the Prediction and Prevention of Sudden Cardiac Death , 2002, Journal of cardiovascular electrophysiology.

[76]  S. Priori,et al.  Low penetrance in the long-QT syndrome: clinical impact. , 1999, Circulation.

[77]  R. Cantu,et al.  Nontraumatic sports death in high school and college athletes. , 1995, Medicine and science in sports and exercise.

[78]  A. Angelini,et al.  Sudden death in the young. Is acute coronary thrombosis the major precipitating factor? , 1994, Circulation.

[79]  Ada Hamosh,et al.  Marfan syndrome caused by a recurrent de novo missense mutation in the fibrillin gene , 1991, Nature.

[80]  D. Atkins,et al.  Cardiovascular preparticipation screening of competitive athletes. A statement for health professionals from the Sudden Death Committee (clinical cardiology) and Congenital Cardiac Defects Committee (cardiovascular disease in the young), American Heart Association. , 1996, Circulation.

[81]  I. Piña,et al.  Statement on exercise: benefits and recommendations for physical activity programs for all Americans. A statement for health professionals by the Committee on Exercise and Cardiac Rehabilitation of the Council on Clinical Cardiology, American Heart Association. , 1996, Circulation.

[82]  D. Corrado,et al.  Clinical profile of congenital coronary artery anomalies with origin from the wrong aortic sinus leading to sudden death in young competitive athletes. , 2000, Journal of the American College of Cardiology.

[83]  Calum A MacRae,et al.  Risk stratification in the long-QT syndrome. , 2003, The New England journal of medicine.

[84]  J. Towbin,et al.  Brugada syndrome: 1992-2002: a historical perspective. , 2003, Journal of the American College of Cardiology.

[85]  Anthony B. Evans,et al.  SUDDEN DEATH IN SQUASH PLAYERS , 1984, The Lancet.

[86]  M. Komajda,et al.  Hypertrophic Cardiomyopathy: Distribution of Disease Genes, Spectrum of Mutations, and Implications for a Molecular Diagnosis Strategy , 2003, Circulation.

[87]  I. Piña,et al.  Statement on exercise. Benefits and recommendations for physical activity programs for all Americans. A statement for health professionals by the Committee on Exercise and Cardiac Rehabilitation of the Council on Clinical Cardiology, American Heart association. , 1992, Circulation.